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中 国 肺 癌 杂 志 2011年 9月 第 14卷 第 9期 Chin J Lung Cancer, September 2011, Vol. 14, No.9 treated by ge tinib as a second-or third-line se ing in advanced NSCLC. CART can be used to identify previously unappreciated patient subsets and is a useful method for dissecting complex clinical situations. Moreover, CART can be used to identify homogeneous patient populations in clinical practice and future clinical trials.
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